FIRST ON FOX: An Israeli public firm says it developed the “only cure for late-stage COVID” and stated that the outcomes of its section II medical trial, disclosed first to Fox News, revealed that sufferers affected by extreme circumstances of COVID-19 had a 94% survival price after being handled with the drug. 

Israeli biotechnology firm Bonus BioGroup’s cell remedy MesenCure was administered to 50 hospitalized COVID-19 sufferers affected by life-threatening pneumonia and respiratory misery, the corporate stated, noting that 47 of these sufferers had survived. 

“These are the most clinically meaningful results presented today for treating severe COVID-19 patients,” Dr. Tomer Bronshtein, the pinnacle of analysis at Bonus BioGroup Ltd., advised Fox News in an unique interview. 

Bronshtein stated the section II medical trial, which just lately concluded and happened in a number of medical facilities in Israel, revealed that MesenCure can “save three out of four people that are at risk of dying” and “can reduce their hospital length of stay by half.” He stated it “will accelerate their healing in a way that will cause less permanent tissue damage and reduce the risk for ‘long COVID.’” 

Israeli biotechnology company Bonus BioGroup’s cell therapy MesenCure 

Israeli biotechnology firm Bonus BioGroup’s cell remedy MesenCure 
(Bonus BioGroup)

The firm famous that for every of the primary 30 individuals in the medical trial, two sufferers, additionally affected by extreme circumstances, with related ages and comorbidities, have been chosen to the “control group,” which didn’t obtain MesenCure.

After analyzing the information, the corporate discovered that Mesencure lowered about 70% of extreme COVID-19 sufferers’ mortality in comparison with the mortality in the group that didn’t obtain the drug. The firm additionally famous that about half of the sufferers with extreme circumstances of COVID-19 who have been handled with the remedy have been discharged from the hospital as much as simply sooner or later after the tip of the treatment. 

FAUCI: COVID-19 HOSPITALIZATIONS RISING AMONG VACCINATED 

“MesenCure is a drug made from living cells,” Bronshtein defined, noting that the cells “are infused into the patient” and as soon as the cells “reach their lungs, they fill the inflammation and start secreting molecules and compounds that soothe this inflammation.”

The MesenCure study found that nearly all COVID-19 patients taking the drug survived.

The MesenCure research discovered that just about all COVID-19 sufferers taking the drug survived.
(iStock, File)

Bronshtein famous that it additionally reduces pneumonia and edema, which helps sufferers “be able to breathe.” 

“In parallel, [the cells] also ameliorate what’s called the cytokine storm, which is the hyperimmune reaction that is aggravated in COVID 19,” he added.  

Bonus BioGroup argued that it’s “necessary to provide a therapeutic option for hospitalized, severe COVID-19 patients” given “vaccines reduce, but do not entirely prevent COVID-19 infection and severe illness, which is also the case with medications designed for at-home treatment of mild COVID-19 that may reduce, but not prevent hospitalization and severe illness.”

PFIZER ASKS U.S. REGULATORS TO AUTHORIZE EXPERIMENTAL COVID-19 PILL

“We have a drug that works and we want to put it to good use,” Bronshtein advised Fox News, including that at the moment MesenCure is barely obtainable to COVID-19 sufferers affected by extreme circumstances by means of compassionate use in Israel. 

Bonus BioGroup has been seeking emergency use approval for the drug in Israel.

Bonus BioGroup has been in search of emergency use approval for the drug in Israel.
(iStock, File)

The Jerusalem Post reported in August that the Health Ministry had permitted the expanded use of MesenCure, which helped 15 out of the 17 sufferers with extreme circumstances of COVID-19 be launched from an Israeli hospital sooner or later after receiving their closing dose.

Following the outcomes of the section II medical trial, Bronshtein stated Bonus BioGroup is now in search of emergency use approval beginning in Israel. The firm can also be persevering with to run section III research. 

“We hope that after we get the approval in Israel, it will be accepted more easily in the United States and in Europe,” Bronshtein advised Fox News.

Bonus BioGroup CEO Shai Meretzki advised Fox News he was “very happy that in less than 18 months we were able to develop a new available therapy for all those severe patients that up to now did not have a solution.”